法国REGATE登记中托珠单抗治疗类风湿关节炎严重感染的危险因素
基于法国REGATE登记中1491例接受托珠单抗治疗的类风湿关节炎患者,计算首次严重感染发生率并用Cox模型筛选独立危险因素。共122例发生125次严重感染,发生率为4.7/100患者年。多因素分析显示基线中性粒细胞绝对值高于5.0×10^9/l、ACPA阴性及合用来氟米特与首次严重感染风险升高独立相关。
要点
- 严重感染发生率为4.7/100患者年,与临床试验报告相近
- 基线ANC>5.0×10^9/l者严重感染风险升高(HR=1.94)
- ACPA阴性及合用来氟米特亦为严重感染预测因素,需加强监测
核心结论
- 托珠单抗治疗类风湿关节炎的实际严重感染率与临床试验相似,基线高ANC、ACPA阴性及合用来氟米特可预测严重感染风险。
研究设计与样本
- 基于法国REGATE登记(REGistry-RoAcTEmra)的观察性研究,纳入1491例接受托珠单抗治疗的类风湿关节炎患者,计算首次严重感染发生率并采用Cox模型分析相关因素,缺失数据采用插补处理。
主要发现
- 1491例患者平均年龄56.6(13.6)岁,122例发生125次严重感染,严重感染发生率为4.7/100患者年。
- 单因素分析中初始ACPA阳性是唯一与严重感染风险降低相关的因素(HR=0.56,95%CI:0.36,0.88)。
- 多因素分析中基线ANC高于5.0×10^9/l(HR=1.94,95%CI:1.32,2.85;P<0.001)、基线ACPA阴性(HR=1.79,95%CI:1.15,2.78;P=0.012)及合用来氟米特(单用来氟米特 vs 无治疗,HR=2.18,95%CI:1.22,3.88;P=0.009)与首次严重感染显著相关。
关键数值与推荐
- 基线ANC高于5.0×10^9/l:HR=1.94,95%CI:1.32,2.85;P<0.001。
- 基线ACPA阴性:HR=1.79,95%CI:1.15,2.78;P=0.012。
- 合用LEF(LEF alone vs no treatment):HR=2.18,95%CI:1.22,3.88;P=0.009。
- 初始ACPA阳性与较低严重感染风险相关:HR=0.56,95%CI:0.36,0.88(单因素分析)。
临床怎么用
- 对拟用或使用托珠单抗的类风湿关节炎患者,应关注基线ANC水平、ACPA状态及是否合用LEF,对高ANC、ACPA阴性或合用LEF者需更严密监测感染。
局限性
- 本文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Observational studies have already reported the risk of serious infections in RA treated with tocilizumab, but in limited samples. The aim of this study was to investigate the predictive risk factors for serious infections in the largest European registry of patients treated with tocilizumab for RA. METHODS: A total of 1491 RA patients included in the French REGistry-RoAcTEmra were analysed to calculate the incidence rate of first serious infections rate after initiation of tocilizumab. To identify independent factors associated with serious infections, a Cox model was performed. RESULTS: Among the 1491 patients, average age 56.6 (13.6) years, 125 serious infections occurred in 122 patients (incidence rate of serious infection: 4.7/100 patient-years). Univariate analysis identified initial ACPA positivity as the only factor associated with a lower risk of serious infection [hazard ratio (HR) = 0.56, 95% CI: 0.36, 0.88]. Other factors significantly associated with a higher risk of serious infections were DAS28, concomitant Leflunomide (LEF) treatment, and absolute neutrophil count (ANC) at baseline. Initial ANC above 5.0 × 109/l (HR = 1.94, 95% CI: 1.32, 2.85; P < 0.001), negative ACPA (HR = 1.79, 95% CI: 1.15, 2.78; P = 0.012) at baseline and concomitant LEF treatment (LEF alone vs no treatment, HR = 2.18, 95% CI: 1.22, 3.88; P = 0.009) remained significantly associated with first serious infections in multivariate analysis after imputation for missing data. CONCLUSION: The rate of first serious infections in current practice is similar to that reported in clinical trials. High ANC (above 5.0 × 109 at baseline), negative ACPA and concomitant therapy with LEF are predictive factors of serious infection, requiring in this case a tighter surveillance.
引用
- Morel J, Constantin A, Baron G, et al. Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE. Rheumatology (Oxford). 2017. PMID: 28957557. doi:10.1093/rheumatology/kex238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。